One systematic review and meta-analysis concluded that HPV-positive HNSCC patients who received PD-1 or PD-L1 therapy demonstrated improved OS compared to HPV-negative patients [30]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.